DISCOVERIES (ISSN 2359-7232), 2020, January-March issue

CITATION: 

Khan F, Singh K, Friedman MT. Artificial Blood: The History and Current Perspectives of Blood Substitutes. Discoveries 2020, Jan-Mar; 8(1); e104. DOI:10.15190/d.2020.1

Submitted: February 5, 2020; Revised: March 7, 2020; Accepted: March 7, 2020; Published: March 18, 2020; 

 GO BACK to 2020, January-March issue

 GO BACK to DISCOVERIES

Artificial Blood: The History and Current Perspectives of Blood Substitutes

Fahad Khan, Kunwar Singh, Mark T. Friedman*

Mount Sinai Health System, Department of Pathology and Laboratory Medicine, Icahn School of Medicine, New York, NY, USA

*Corresponding author: Mark T. Friedman, DO, Mount Sinai Health System, Department of Pathology and Laboratory Medicine, Icahn School of Medicine, 1000 Tenth Avenue New York, NY 10019; Phone: 212-523-7242; Email: mark.friedman@mountsinai.org


Disclosure: Corresponding author, Prof. Mark Friedman, is a Senior Editor of the journal Discoveires.

Abstract

Blood transfusions are one of the most common procedures performed in hospitalized patients. Yet, despite all of the measures taken to ensure the safety of the blood supply, there are known risks associated with transfusions, including infectious and noninfectious complications. Meanwhile, issues with blood product availability, the need for compatibility testing, and the storage and transport requirements of blood products, have presented challenges for the administration of blood transfusions. Additionally, there are individuals who do not accept blood transfusions (e.g., Jehovah’s Witnesses). Therefore, there is a need to develop alternative agents that can reliably and safely replace blood. However, although there have been many attempts to develop blood substitutes over the years, there are currently no such products available that have been approved by the United States Food and Drug Administration (FDA). However, a more-recently developed hemoglobin-based oxygen carrier has shown promise in early clinical trials and has achieved the status of “Orphan Drug” under the FDA.


Access full text of the manuscript here: 

References

1. Chen J-Y, Scerbo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics. 2009;64(8):803-13.
2. United States Food and Drug Administration. Guidance for Industry: Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. July 2018. Accessed on March 9, 2020. Available at: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Revised-Recommendations-for-Reducing-the-Risk-of-Zika-Virus-Transmission-by-Blood-and-Blood-Components--Guidance-for-Industry.pdf  
3. Moritz ED, Winton CS, Tonnetti L, Townsend RL, Berardi VP, Hewins ME, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016;375(23):2236-45.
4. Gao C, Li L, Chen B, Song H, Cheng J, Zhang X, Sun Y. Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient Prefer Adherence. 2014;8:513-7.
5. Toy P, Lowell C. TRALI – Definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol. 2007;21(2):183-93.
6. Verra F, Angheben A, Martello E, Giorli G, Perandin F, Bisoffi Z. A systemic review of transfusion-transmitted malaria in non-endemic areas. Malar J. 2018;17:36.
7. Annen K, Friedman K, Eshoa C, Horowitz M, Gottschall M, Straus T. Two cases of transfusion-transmitted Anaplasma phagocytophilum. Am J Clin Pathol. 2012;137(4):562-5.
8. Seed CR, Hewitt PE, Dodd RY, Houston F, Cervenakova L. Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sang. 2018;113(3):220-31.
9. Institute for Quality and Efficiency in Health Care (IQWiG). What Does Blood Do? InformedHealth.org. Created January 21, 2010, updated January 7, 2015. Accessed on March 9, 2020. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK279392/ 
10. Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science. 1966 Jun 24;152(3730):1755–6.
11. Riess JG. Understanding the Fundamentals of Perfluorocarbons and Perfluorocarbon Emulsions Relevant to In Vivo Oxygen Delivery. Artif Cells Blood Substit Biotechnol. 2005 Jan 1;33(1):47–63.
12. Kerins DM. Role of the Perfluorocarbon Fluosal-DA in Coronary Angioplasty. Am J Med Sci. 1994 Mar 1;307(3):218–21.
13. Honda K, Hoshino S, Shoji M, Usuba A, Motoki R, Tsuboi M, Inoue H, Iwaya F. Clinical Use of a Blood Substitute. N Engl J Med. 1980 Aug 14;303(7):391-2.
14. Mitsuno T, Ohyanagi H, Naito R. Clinical Studies of A Perfluorochemical Whole Blood Substitute (Fluosol-DA). Ann Surg. 1982 Jan;195(1):60–9.
15. Riess JG. Oxygen carriers (“blood substitutes”)--raison d’etre, chemistry, and some physiology. Chem Rev. 2001 Sep;101(9):2797–920.
16. Spahn DR, Waschke KF, Standl T, Motsch J, Van Huynegem L, Welte M, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology. 2002 Dec;97(6):1338–49.
17. Riess JG. Perfluorocarbon-based Oxygen Delivery. Artif Cells Blood Substit Biotechnol. 2006 Jan 1;34(6):567–80.
18. Fabian TC. Perfluorocarbons. J Trauma. 2011 May;70(5 Suppl):S42-44.
19. Castro CI, Briceno JC. Perfluorocarbon-Based Oxygen Carriers: Review of Products and Trials. Artif Organs. 2010;34(8):622–34.
20. Latson GW. Perftoran (Vidaphor)—Introduction to Western Medicine. Shock. 2019 Oct;52(1S):65.
21. Lang ME, Korecky B, Anderson PJ, Biro GP. Stroma-Free Hemoglobin Solutions Prepared by Crystallization and Ultrafiltration Methods; Comparison of Composition and Coronary Vasoconstrictor Potency. In: Oxygen Transport to Tissue XII. Springer, Boston, MA; 1990; p. 225–36. (Advances in Experimental Medicine and Biology). Available from: https://link.springer.com/ chapter/10.1007/978-1-4684-8181-5_28
22. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther. 1978 Jan;23(1):73–80.
23. Stowell C. Blood substitutes: time for a deep breath. Transfusion (Paris). 2008 Apr;48(4):574–5.
24. Chang TMS. Future generations of red blood cell substitutes. J Intern Med. 2003;253(5):527–35.
25. Benesch RE, Benesch R, Yu CI. Oxygenation of hemoglobin in the presence of 2,3- diphosphoglycerate. Effect of temperature, pH, ionic strength, and hemoglobin concentration. Biochemistry. 1969 Jun 1;8(6):2567–71.
26. Simoni J, Simoni G, Moeller JF. Intrinsic Toxicity of Hemoglobin: How to Counteract It. Artif Organs. 2009;33(2):100–9.
27. Browdie D, Smith H. Stroma-free hemoglobin: Simplified preparation and in vivo and in vitro effects on coagulation in rabbits. Am J Surg. 1975 Apr 1;129(4):365–8.
28. Chang TMS. Blood Substitutes Based on Modified Hemoglobin Prepared by Encapsulation or Crosslinking: an Overview. Biomater Artif Cells Immobilization Biotechnol. 1992 Jan 1;20(2–4):159– 79.
29. Jahr JS, Walker V, Manoochehri K. Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anesthesiol. 2007 Aug;20(4):325–30.
30. Mer M, Hodgson E, Wallis L, Jacobson B, Levien L, Snyman J, et al. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion (Paris). 2016 Oct 1;56(10):2631–6.
31. Van Hemelrijck J, Levien LJ, Veeckman L, Pitman A, Zafirelis Z, Standl T. A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter, red blood cell controlled trial in noncardiac surgery patients. Anesthesia & Anelgesia. 2014;119(4):766-76.
32. Vincent J, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-hellmann A, et al. Multicenter, Randomized, Placebo-controlled Phase Iii Study of Pyridoxalated Hemoglobin Polyoxyethylene in Distributive Shock (phoenix)*. Crit Care Med. 2015 Jan 1;43(1):57–64.
33. Winslow RM. Blood substitutes — a moving target. Nat Med. 1995 Nov;1(11):1212–5.
34. Highsmith FA, Driscoll CM, Chung BC, Chavez MD, Macdonald VW, Manning JM, et al. An Improved Process for the Production of Sterile Modified Haemoglobin Solutions. Biologicals. 1997 Sep 1;25(3):257–68.
35. Nelson D, Azari M, Brown R, Burhop K, Bush S, Catarello J, et al. Preparation and Characterization of Diaspirin Cross-Linked Hemoglobin Solutions for Preclinical Studies. Biomater Artif Cells Immobilization Biotechnol. 1992 Jan 1;20(2–4):423–7.
36. Boykins RA, Buehler PW, Jia Y, Venable R, Alayash AI. O-raffinose crosslinked hemoglobin lacks site-specific chemistry in the central cavity: structural and functional consequences of beta93Cys modification. Proteins. 2005 Jun 1;59(4):840–55.
37. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, et al. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000 Jul;28(7):2283–92.
38. Hill SE, Gottschalk LI, Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2002 Dec;16(6):695–702.
39. Chang TMS. Hemoglobin-based Red Blood Cell Substitutes. Artif Organs. 2004;28(9):789–94.
40. Tsai AG, Sakai H, Wettstein R, Kerger H, Intaglietta M. An Effective Blood Replacement Fluid That Targets Oxygen Delivery, Increases Plasma Viscosity, and Has High Oxygen Affinity. Transfus Altern Transfus Med. 2004;5(6):507–13.
41. Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion (Paris). 2001;41(2):287–99.
42. Moore FA, McKinley BA, Moore EE. The next generation in shock resuscitation. Lancet Lond Engl. 2004 Jun 12;363(9425):1988–96.
43. Moore EE. Blood substitutes: The future is now. J Am Coll Surg. 2003 Jan;196(1):1–17.
44. Alayash AI. Hemoglobin-based blood substitutes and the hazards of blood radicals. Free Radic Res. 2000 Oct;33(4):341–8.
45. Rifkind JM, Mohanty JG, Nagababu E. The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions. Front Physiol. 2015 Jan 14;5:500.
46. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol. 1999 Jun;17(6):545–9.
47. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke. 1999 May;30(5):993– 6.
48. Olofsson C, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, et al. A Multicenter Clinical Study of the Safety and Activity of Maleimide-Polyethylene Glycol–modified Hemoglobin (Hemospan®) in Patients Undergoing Major Orthopedic Surgery. Anesthesiol J Am Soc Anesthesiol. 2006 Dec 1;105(6):1153–63.
49. Belcher JD, Young M, Chen C, Nguyen J, Burhop K, Tran P, et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood. 2013 Oct 10;122(15):2757–64.
50. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG- Hb conjugate. Transfusion (Paris). 2003;43(4):509–16.
51. Mitchell P, Weiskopf R, Zapol WM. NIH/FDA/DOD Interagency Working Group on Oxygen Therapeutics. In: Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics. Springer, Berlin, Heidelberg; 2013; p. 141–7. Available from: https://link.springer.com/chapter/10.1007/978-3-642-40717-8_8
52. Acharya SA, Friedman JM, Manjula BN, Intaglietta M, Tsai AG, Winslow RM, et al. Enhanced molecular volume of conservatively PEGylated Hb: (SP-PEG 5K)6-HbA is non-hypertensive. Artificial Cells, Blood Substitutes, and Biotechnology. 2005;33(3):239-55.
53. Olofsson CI, Górecki AZ, Dirksen R, Kofranek I, Majewski JA, Mazurkiewicz T, et al. Evaluation of MP4OX for Prevention of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty with Spinal Anesthesia: A Randomized, Double-blind, Multicenter Study. Anesthesiology. 2011 May;114(5):1048–63.
54. Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty. ClinicalTrials.gov. Accessed on July 17, 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT00421200
55. Dhar R, Misra H, Diringer MN. SANGUINATETM (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Neurocrit Care. 2017 Dec;27(3):341–9.
56. Ananthakrishnan R, Li Q, O’Shea KM, Quadri N, Wang L, Abuchowski A, et al. Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice. Artif Cells Nanomedicine Biotechnol. 2013 Dec 1;41(6):428–36.
57. Abu J, Woodle ES, Leino AD, Brailey P, Tremblay S, Dorst T, et al. A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. Clin Transplant. 2018;32(1).
58. Buontempo P, Jubin RG, Buontempo C, Real R, Kazo F, O’Brien S, et al. Pegylated Carboxyhemoglobin Bovine (SANGUINATE((R))) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis. Blood. 2017 Dec 7;130.
59. Abuchowski A. SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. Artif Organs. 41(4):346–50.
60. Kato RM, Hofstra T, Meiselman HJ, Forman HJ, Abuchowski A, Parmar DV, et al. Infusion of Pegylated Bovine Carboxyhemoglobin (PEG-COHb) Is Associated with Rapid Reversal of Progressive Acute Chest Syndrome in a Jehovah’s Witness Patient with Hemoglobin SC Sickle Cell Disease. Blood. 2015 Dec 3;126(23):4541–4541.
61. Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting; Accessed on Dececember 22, 2019. Available from: https://prolongpharma.com/prolong-pharmaceuticals-announces-completion-of-enrollment-in-phase-ii-study-of-sanguinate-in-the-treatment-of-sickle-cell-disease-patients-with-vaso-occlusive-crisis-in-an-ambulatory-setting/
62. A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients. ClinicalTrials.gov. Accessed on Dec. 22, 2019. Available from: https://clinicaltrials.gov/ct2/show/ NCT02672540
63. Pan D, Rogers S, Misra S, Vulugundam G, Gazdzinski L, Tsui A, et al. Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results. Blood. 2016 Dec 2;128(22):1027–1027.
64. Mackenzie CF, Dubé GP, Pitman A, Zafirelis M. Users Guide to Pitfalls and Lessons Learned About HBOC-201 During Clinical Trials, Expanded Access, and Clinical Use in 1,701 Patients: SHOCK. 2019; 52:92–9.
65. Evaluation of a Marine OXYgen Carrier (Hemo2Life®) for Organ Preservation: First Use in Kidney Transplantation in Humans. ATC Abstracts. Accessed on September 6, 2019. Available from: https://atcmeetingabstracts.com/abstract/evaluation-of-a-marine-oxygen-carrier-hemo2life-for-organ-preservation-first-use-in-kidney-transplantation-in-humans/
66. Wollocko H, Anvery S, Wollocko J, Harrington JM, Harrington JP. Zero-link polymerized hemoglobin (OxyVita®Hb) stabilizes the heme environment: potential for lowering vascular oxidative stress. Artif Cells Nanomedicine Biotechnol. 2017 May 19;45(4):701–9.
67. Yadav VR, Nag O, Awasthi V. Biological evaluation of liposome-encapsulated hemoglobin (LEH)
surface-modified with a novel PEGylated non-phospholipid amphiphile. Artif Organs. 2014 Aug;38(8):625–33.
68. Masayuki G, Takeo A, Teruyuki K, Ryosuke F, Kota K, Daisuke S, et al. Novel Hemoglobin-Based Oxygen Carrier Bound With Albumin Shows Neuroprotection With Possible Antioxidant Effects. Stroke. 2018 Aug 1;49(8):1960–8.

News & Events Latest news from Discoveries

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10th, 2019. Our next step is ISI indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.